Serum IL-6 and IL-23 Levels and Their Correlation with Angiogenic Cytokines and Disease Activity in Ankylosing Spondylitis, Psoriatic Arthritis, and SAPHO Syndrome

Table 3

A logistic regression model of the OR of the increased serum level of interleukin-23 in spondyloarthritis patients.

Covariates	Serum IL-23 > 0.0 pg/mL		Serum IL-23 ≥ 2.5 pg/mL
	OR (95% CI)	P	OR (95% CI)	P
Ankylosing spondylitis	1.83 (1.02–3.29)	0.04	2.07 (1.06–4.05)	0.03
Psoriatic arthritis	0.73 (0.41–1.31)	0.29	0.71 (0.36–1.40)	0.33
SAPHO	0.47 (0.18–1.26)	0.135	0.27 (0.06–1.21)	0.08
CRP ≥ 5 mg/L	1.02 (0.57–1.83)	0.94	0.93 (0.48–1.81)	0.82
BASDAI ≥ 4	1.52 (0.80–2.86)	0.19	1.47 (0.70–3.08)	0.30
NSAIDs	1.40 (0.70–2.80)	0.35	2.42 (1.15–5.07)	0.02
Sulfasalazine	1.08 (0.60–1.93)	0.79	0.58 (0.29–1.15)	0.12
Methotrexate	0.70 (0.37–1.30)	0.25	0.92 (0.45–1.86)	0.81

IL-23: interleukin-23.
OR: odds ratio.
95% CI: 95% confidence interval.
NSAIDs: nonsteroidal anti-inflammatory drugs.